Arrowhead Pharmaceuticals Stock Z Score
| ARWR Stock | USD 23.78 0.14 0.59% |
Arrowhead | Z Score |
Arrowhead Pharmaceuticals Company Z Score Analysis
Arrowhead Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Arrowhead Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Arrowhead Pharmaceuticals is extremely important. It helps to project a fair market value of Arrowhead Stock properly, considering its historical fundamentals such as Z Score. Since Arrowhead Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arrowhead Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arrowhead Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Arrowhead Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Arrowhead Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.Arrowhead Pharmaceuticals is currently under evaluation in z score category among related companies.
Arrowhead Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arrowhead Pharmaceuticals from analyzing Arrowhead Pharmaceuticals' financial statements. These drivers represent accounts that assess Arrowhead Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arrowhead Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.6B | 2.6B | 4.3B | 3.5B | 3.1B | 3.3B | |
| Enterprise Value | 1.6B | 2.4B | 4.2B | 3.5B | 3.1B | 3.3B |
Arrowhead Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Arrowhead Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arrowhead Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arrowhead Pharmaceuticals' value.| Shares | Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 1.3 M | Northern Trust Corp | 2023-12-31 | 1.2 M | Rokos Capital Management Llp | 2023-12-31 | 1.2 M | Venbio Select Advisor Llc | 2023-12-31 | 1.1 M | Artal Group S A | 2023-12-31 | 1 M | Bank Of New York Mellon Corp | 2023-12-31 | 957.9 K | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 951.3 K | Ameriprise Financial Inc | 2023-12-31 | 928.6 K | Woodline Partners Lp | 2023-12-31 | 927.2 K | Blackrock Inc | 2023-12-31 | 13.3 M | Vanguard Group Inc | 2023-12-31 | 10.7 M |
Arrowhead Fundamentals
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.63) % | ||||
| Operating Margin | (38.45) % | ||||
| Current Valuation | 3.16 B | ||||
| Shares Outstanding | 123.9 M | ||||
| Shares Owned By Insiders | 4.40 % | ||||
| Shares Owned By Institutions | 66.86 % | ||||
| Number Of Shares Shorted | 8.87 M | ||||
| Price To Earning | 482.39 X | ||||
| Price To Book | 19.08 X | ||||
| Price To Sales | 16.84 X | ||||
| Revenue | 240.74 M | ||||
| Gross Profit | 240.74 M | ||||
| EBITDA | (188.16 M) | ||||
| Net Income | (209.28 M) | ||||
| Cash And Equivalents | 416.5 M | ||||
| Cash Per Share | 3.93 X | ||||
| Total Debt | 115.17 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 3.37 X | ||||
| Book Value Per Share | 1.49 X | ||||
| Cash Flow From Operations | (153.89 M) | ||||
| Short Ratio | 5.77 X | ||||
| Earnings Per Share | (2.77) X | ||||
| Price To Earnings To Growth | (1.32) X | ||||
| Target Price | 55.38 | ||||
| Number Of Employees | 525 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 2.95 B | ||||
| Total Asset | 765.55 M | ||||
| Retained Earnings | (1.03 B) | ||||
| Working Capital | 110.03 M | ||||
| Current Asset | 90.5 M | ||||
| Current Liabilities | 25.64 M | ||||
| Net Asset | 765.55 M |
About Arrowhead Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Arrowhead Stock
| 0.74 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.7 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.67 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.6 | ELYM | Eliem Therapeutics | PairCorr |
| 0.57 | NRSNW | NeuroSense Therapeutics | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arrowhead Pharmaceuticals Piotroski F Score and Arrowhead Pharmaceuticals Valuation analysis. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 1.697 | Quarterly Revenue Growth (0.94) | Return On Assets (0.25) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.